


Structures for

6251923

=> d scan


L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, 5-(acetyloxy)-N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-.alpha.-oxo- (9CI)
MF C24 H16 Cl2 F N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):16

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-carboxamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-1-[(4-methoxyphenyl)methyl]- (9CI)
MF C22 H17 Cl2 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, N-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1-[(4-fluorophenyl)methyl]-5-hydroxy-.alpha.-oxo- (9CI)
MF C24 H14 Cl2 F4 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(2,6-dichlorophenyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy-.alpha.-oxo- (9CI)
 MF C23 H15 Cl2 F N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-1-(1-methylethyl)-.alpha.-oxo- (9CI)
 MF C18 H15 Cl2 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-1-[(3-nitrophenyl)methyl]-.alpha.-oxo-, monosodium salt (9CI)
 MF C22 H14 Cl2 N4 O5 . Na




L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, 1-[(2,6-difluorophenyl)methyl]-5-hydroxy-.alpha.-oxo-N-4-pyridinyl- (9CI)
 MF C22 H15 F2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy-.alpha.-oxo-, monosodium salt (9CI)
MF C22 H14 Cl2 F N3 O3 Na




best
5-OH

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Phosphodiesterase, adenosine cyclic 3',5'-phosphate (9CI)
MF Unspecified
CI MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-methoxy-.alpha.-oxo- (9CI)
MF C23 H16 Cl2 F N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-6-hydroxy-.alpha.-oxo- (9CI)
MF C22 H14 Cl2 F N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, N-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1-[(4-fluorophenyl)methyl]-5-hydroxy-.alpha.-oxo- (9CI)
MF C24 H14 Cl2 F4 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Indole-3-acetamide, 1-(cyclopentylmethyl)-N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-.alpha.-oxo- (9CI)
MF C21 H19 Cl2 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-5-hydroxy-.alpha.-oxo-
 1-propyl- (9CI)
 MF C18 H15 Cl2 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(2,6-
 difluorophenyl)methyl]-5-hydroxy-.alpha.-oxo- (9CI)
 MF C22 H13 Cl2 F2 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-.alpha.,5-dihydroxy- (9CI)
 MF C22 H16 Cl2 F N3 O3





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 17 ANSWERS REGISTRY COPYRIGHT 2002 ACS
 IN 1H-Indole-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-5-hydroxy-.alpha.-oxo- (9CI)
 MF C22 H14 Cl2 F N3 O3
 CI COM





ALL ANSWERS HAVE BEEN SCANNED



chain nodes :
 10 11 13 14 15 16 17
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 7-13 10-11 13-14 14-15 15-16 16-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 6-9 7-13 8-9 13-14 14-15 15-16 16-17
 exact bonds :
 5-7 7-8 10-11
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS
 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS



chain nodes :
 10 11 13 14 15 16 17
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 7-13 10-11 13-14 14-15 15-16 16-17
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 6-9 7-13 8-9 13-14 14-15 15-16 16-17
 exact bonds :
 5-7 7-8 10-11
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS
 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS

kwic 1-2

→ L3 ANSWER 1 OF 2 USPATFULL
PI US 5464861 19951107
AN 95:99174 USPATFULL
TI 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IN Dobrusin, Ellen M., Ann Arbor, MI, United States
Showalter, Howard D. H., Ann Arbor, MI, United States
Denny, William A., Pakuranga, New Zealand
Palmer, Brian D., Glendene, New Zealand
Rewcastle, Gordon W., Manurewa, New Zealand
Tercel, Moana, Forrest Hill, New Zealand
Thompson, Andrew M., Mount Eden, New Zealand
PA Warner-Lambert, Ann Arbor, MI, United States (U.S. corporation)
PI US 5464861 19951107
AI US 1993-94792 19930809 (8)
RLI Continuation-in-part of Ser. No. US 1992-926015, filed on 6 Aug 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: McKane, Joseph K.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Thioindoles (2-selenoindoles) and analogous 2-indolinethione (2-indolineselenone) and polysulfide (selenide) compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for inhibiting protein kinase dependent disease in a mammal or treating aberrant cell growth in a mammal, using said compositions, are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD Similar demethylation/acetylation of 5-methoxy-1-methyl-2-oxindole [VII: R.sub.1-5 =OMe, R.sub.3 =Me] gave 5-acetoxy-1-methyl-2-oxindole [VII: R.sub.1 =5-OAc, R.sub.3 =Me] (70% yield); mp (EtOAc/petroleum ether) 104.degree.-106.degree..
DETD Similar demethylation/acetylation of 6-methoxy-1-methyl-2-oxindole [VII: R.sub.1 =6-OMe, R.sub.3 =Me] gave 6-acetoxy-1-methyl-2-oxindole [VII: R.sub.1 =6-OAc, R.sub.3 =Me] (81% yield); mp 119.degree.-121.degree. C.
DETD Similar demethylation/acetylation of 7-methoxy-1-methyl-2-oxindole [VII: R.sub.1 =7-OMe, R.sub.3 =Me] gave 7-acetoxy-1-methyl-2-oxindole [VII: R.sub.1 =7-OAc, R.sub.3 =Me] (68% yield); mp 95.degree.-97.degree. C.
NCL NCLM: 514/414.000
NCLS: 514/339.000; 514/365.000; 514/369.000; 514/397.000; 514/418.000; 546/256.000; 546/272.400; 546/277.700; 546/278.100; 546/304.000; 548/181.000; 548/312.100; 548/460.000; 548/461.000; 548/462.000; 548/486.000